Skip to main content
Fig. 1 | Cell & Bioscience

Fig. 1

From: PTEN mutant non-small cell lung cancer require ATM to suppress pro-apoptotic signalling and evade radiotherapy

Fig. 1

PTEN alterations; impact on pathways and radiation resistance. A PTEN alteration frequency of NSCLC from cBioportal, https://www.cbioportal.org/. Analysis of Lung Squamous Cell Carcinoma (SCC) and Adenocarcinoma (ADC). B Kaplan–Meier Plot of lung cancer patient survival stratified by PTEN (204054_at) expression. Median survival in the ADC cohort of the low PTEN expression 61.3 months, of high expression 175 months. Median survival in the SCC cohort of the low PTEN expression 42 months, of high expression 72.3 months. The p-value was calculated using a logrank test. HR: hazard ratio. Generated with the online tool https://kmplot.com. C Schematic representation of the CRISPR/Cas9 genome editing strategy to delete PTEN in the human lung cell line BEAS-2B targeting exon 1 and exon 4. D Immunoblot of virus transfected, blasticidin selected and clonogenic isolated BEAS-2B cells, generated with the described method (Additional file 1: Fig. 2B). Control: WT: Epithelial transformed BEAS-2B PTENwt cells. Actin as loading control. E Receptor-tyrosine-kinase signaling cascade of the MAPK-pathway and PI3K/Akt pathway. Numbers next to the Enzymes show the percentage of genetic alteration of the coding genes. Data generated with the free online tool www.cbioportal.org. F Colony formation assay BEAS-2B clone II1 (PTENhetero, light blue) and III3 (PTENhomo, blue) compared to vector control (black). SF 2: Surviving fraction at 2 Gy. D25: Dose in Gy with 25% survival. Error bars: Standard deviation. n = 3. Also see Additional file 1: Fig. S1

Back to article page